Skip to content
Screener

Relay Therapeutics, Inc. RLAY Operating Lease Liabilities

Operating Lease Liabilities at other companies

Schrodinger logo
SchrodingerSDGR
$91.5M-6.1%
PVL
Palvella TherapeuticsPVLA
$375K
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$39.19M-26.6%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
$137.74M+15.1%
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$3.78M-18.4%
Immunome logo
ImmunomeIMNM
$3.69M-22.6%

Other financials

Income statement

See full
Revenue$350.0K-48.3%
Operating income-$90.8M-18.2%
Net income-$83.7M-18.9%
EPS (diluted)-$0.410.0%

Balance sheet

See full
Cash & equivalents$121.2M+6.4%
Total debt$30.7M-10.3%
Total equity$890.0M+33.7%
Total assets$967.5M+32.7%

Cash flow

See full
Operating cash flow-$54.1M+2.1%
CapEx$1.0K
Free cash flow-$44.9M+22.5%

Valuation

See full
Market cap$4.3B+611%
Enterprise value$4.21B+702%
P/S415.9×+343×

Profitability

See full
Operating margin-2,999.4%-637pp
Net margin-2,763.6%-568pp
FCF margin-1,536%-429pp

Returns & leverage

See full
Return on equity-36.8%-6.3pp
Debt / equity0.0×
Current ratio18.3×-2.7×

Where this comes from

Reported directly by Relay Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.

The source filing: Relay Therapeutics, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:15 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-338056
Line itemJune 30, 2026December 31, 2025
Operating lease liabilities4,0143,765
Other current liabilities1,252463
Total current liabilities50,80425,578
Operating lease liabilities, net of current portion26,64428,693
Total liabilities77,44854,271
Commitments and contingencies (Note 9)
Stockholders’ equity:
Undesignated preferred stock, $0.001 par value, 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares issued and outstanding as of June 30, 2026 and December 31, 2025

Item 1. Financial Statements.

FAQ

What is Relay Therapeutics, Inc.'s operating lease liabilities?
Relay Therapeutics, Inc. (RLAY) reported operating lease liabilities of $26.64M in Q2 2026.
How has Relay Therapeutics, Inc.'s operating lease liabilities changed year-over-year?
Relay Therapeutics, Inc.'s operating lease liabilities decreased by 13.1% year-over-year, from $30.66M to $26.64M.
What is the long-term trend for Relay Therapeutics, Inc.'s operating lease liabilities?
Over 5 years (2020 to 2025), Relay Therapeutics, Inc.'s operating lease liabilities has grown at a 4.6% compound annual growth rate (CAGR), from $22.9M to $28.69M.
What does operating lease liabilities mean?
Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.

Ask your AI about Relay Therapeutics, Inc.'s operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude